HOME >> BIOLOGY >> NEWS
Rapid syphilis testing in Haiti will prevent congenital disease and stillbirths

NEW YORK (May 28, 2007) -- Congenital syphilis is a major preventable public health problem in many developing countries, frequently causing stillbirths or neonatal death and disabling children who survive. Often undiagnosed or untreated, syphilis is passed from mother to child -- even when mothers take part in prenatal programs to prevent the spread of HIV.

Now, new research from Weill Cornell Medical College and the Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) published in the May issue of the open-access journal PLoS Medicine finds that integrating a new rapid syphilis test into prenatal HIV testing programs in Haiti can prevent more than 2,000 cases of stillbirth, neonatal death or congenital syphilis.

"We have shown that by working with the HIV prevention program infrastructure, we can better prevent transmission of syphilis from mother to child at minimal incremental cost. These findings not only give guidance to public health efforts in Haiti, but may serve as a model for projecting the benefits of similar efforts in Africa and in other resource-poor settings," says Dr. Bruce R. Schackman, lead author of the study and associate professor and chief of the Division of Health Policy in the Department of Public Health at Weill Cornell Medical College.

Researchers compared three strategies for screening pregnant women for syphilis. The first strategy, the standard of care in rural Haitian areas without access to syphilis laboratory testing, is assessing symptoms and treating if symptoms are found. The second, considered the standard in urban areas, is a blood test for antibody response to the syphilis bacterium -- an approach that requires a one-week waiting period for follow-up and treatment. The third strategy is rapid testing that permits immediate diagnosis and treatment initiation at a single clinic visit.

According to the World Health Organization (WHO), there are more than 2
'"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
28-May-2007


Page: 1 2 3

Related biology news :

1. Rapid evolution of defense genes in plants may produce hybrid incompatibility
2. Rapid-fire jaws propel ants to safety
3. Biological diversity and human health; Rapid autopsy program; Snake bites and more
4. Rapid genomic and physiological responses for social dominance
5. How a zebra lost its stripes: Rapid evolution of the quagga
6. Rapid, new test develped for inherited immune deficiency
7. Modular leukemia drug shows promise in early testing
8. XDx to present recent success with AlloMap molecular expression testing
9. Potential genetic testing for substance abuse raises hope, concern
10. U-M team: Genetic testing sheds light on degenerative eye disease
11. Antiretroviral resistance testing in HIV infected patients improves health and saves costs

Post Your Comments:
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical ... building for its School of Medicine. Funding for this ... capital campaign that will be publicly launched next summer. ... located in the former 60 series R.J. Reynolds Tobacco ... Quarter. Construction will begin immediately with plans to be ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/13/2014)... New York (PRWEB) December 13, 2014 ... its global network and Cold Chain capabilities, and is ... Tower in Paris, France, to serve Life Science clients ... facility equipped with a controlled-ambient warehouse, will provide 24/7 ... for vaccines and investigational drugs, patient-clinical specimens, API, following ...
(Date:12/13/2014)... Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ... "Glucose Sensors: the Next Generation" report to ... The convergence of small-scale electronics ... for a better future to millions of diabetes ... glucose levels accurately and reliably have the capability ...
(Date:12/13/2014)... and SAN ANTONIO , ... (Janssen) today announced the presentation of data at the ... 3 EPO-ANE-3010 study evaluating epoetin alfa plus best supportive ... in patients with metastatic breast cancer receiving standard chemotherapy. ... which was to rule out a 15 percent or ...
(Date:12/12/2014)... 2014 Graphite Metallizing Corporation, the manufacturer ... and process equipment, has appointed Kirk Staller as Sales ... Canada. Staller holds a B.S. degree from Purdue University ... market place, much of it with a manufacturer of ... Michigan office. , “We are pleased to ...
Breaking Biology Technology:Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2
Cached News: